Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor

MLA

le Sève, Julien Denis, et al. “Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor.” Thrombosis and Haemostasis, vol. 123, no. 11, Nov. 2023, pp. 1049–56. EBSCOhost, https://doi.org/10.1055/s-0043-1769609.

APA

le Sève, J. D., Guédon, A. F., Bordenave, S., Agard, C., Connault, J., Pistorius, M.-A., Quéreux, G., & Espitia, O. (2023). Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor. Thrombosis and Haemostasis, 123(11), 1049–1056. https://doi.org/10.1055/s-0043-1769609

Chicago

le Sève, Julien Denis, Alexis F. Guédon, Stéphanie Bordenave, Christian Agard, Jérôme Connault, Marc-Antoine Pistorius, Gaelle Quéreux, and Olivier Espitia. 2023. “Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor.” Thrombosis and Haemostasis 123 (11): 1049–56. doi:10.1055/s-0043-1769609.